
Prenetics Global Limited (NASDAQ:PRE – Free Report) – Equities researchers at Sidoti issued their Q2 2026 earnings per share (EPS) estimates for shares of Prenetics Global in a report released on Monday, June 22nd. Sidoti analyst A. Hantman anticipates that the company will post earnings per share of ($0.91) for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.03) per share. Sidoti also issued estimates for Prenetics Global’s FY2026 earnings at ($2.12) EPS.
Prenetics Global (NASDAQ:PRE – Get Free Report) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%. The firm had revenue of $35.95 million during the quarter, compared to the consensus estimate of $36.00 million.
View Our Latest Stock Report on Prenetics Global
Prenetics Global Price Performance
Shares of PRE stock opened at $19.72 on Thursday. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63. The stock has a market capitalization of $332.68 million, a price-to-earnings ratio of -4.31 and a beta of 0.24. The company’s fifty day simple moving average is $18.44 and its two-hundred day simple moving average is $18.21.
Institutional Investors Weigh In On Prenetics Global
Large investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in Prenetics Global during the 1st quarter valued at $48,000. Wells Fargo & Company MN purchased a new position in shares of Prenetics Global during the fourth quarter valued at approximately $47,000. JPMorgan Chase & Co. bought a new stake in Prenetics Global in the third quarter worth $65,000. Manatuck Hill Partners LLC bought a new position in Prenetics Global in the 4th quarter worth about $170,000. Finally, T3 Companies LLC purchased a new stake in shares of Prenetics Global during the fourth quarter valued at approximately $170,000. 25.01% of the stock is currently owned by institutional investors.
Prenetics Global announced that its board has approved a share buyback program on Friday, March 6th that allows the company to repurchase $40.00 million in shares. This repurchase authorization allows the company to buy up to 15.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.
About Prenetics Global
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Read More
- Five stocks we like better than Prenetics Global
- Washington’s Quantum Push Puts IBM and IonQ on the Throne
- FedEx’s Earnings Drop May Be Missing the Bigger Freight Story
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
